Your browser doesn't support javascript.
loading
Management and outcomes of patients with left atrial appendage thrombus prior to percutaneous closure.
Marroquin, Luis; Tirado-Conte, Gabriela; Pracon, Radoslaw; Streb, Witold; Gutierrez, Hipolito; Boccuzzi, Giacomo; Arzamendi-Aizpurua, Dabit; Cruz-González, Ignacio; Ruiz-Nodar, Juan Miguel; Kim, Jung-Sun; Freixa, Xavier; Lopez-Minguez, Jose Ramon; De Backer, Ole; Ruiz-Salmeron, Rafael; Dominguez, Antonio; McInerney, Angela; Peral, Vicente; Estevez-Loureiro, Rodrigo; Fernandez-Nofrerias, Eduard; Freitas-Ferraz, Afonso B; Saia, Francesco; Huczek, Zenon; Gheorghe, Livia; Salinas, Pablo; Demkow, Marcin; Delgado-Arana, Jose R; Fernandez Peregrina, Estefania; Kalarus, Zbibniew; Elvira Laffond, Ana; Jang, Yangsoo; Fernandez Camacho, Jose Carlos; Lee, Oh-Hyun; Hernández-Garcia, Jose M; Mas-Llado, Caterina; Caneiro Queija, Berenice; Amat-Santos, Ignacio J; Dabrowski, Maciej; Rodés-Cabau, Josep; Nombela Franco, Luis.
Afiliación
  • Marroquin L; Interventional Cardiology. Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.
  • Tirado-Conte G; Interventional Cardiology. Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.
  • Pracon R; Department of Coronary and Structural Heart Diseases, National Institute of Cardiology, Warsaw, Poland.
  • Streb W; Silesian Centre for Heart Disease, Zabrze, Poland.
  • Gutierrez H; Cardiology, Clinic University Hospital, Valladolid, Spain.
  • Boccuzzi G; Cardiology, Ospedale San Giovanni Bosco, Turin, Italy.
  • Arzamendi-Aizpurua D; Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Cruz-González I; Cardiology, Hospital Universitario de Salamanca, IBSAL, CIBER CV, Salamanca, Spain.
  • Ruiz-Nodar JM; Cardiology, Hospital General Universitari d'Alacant, Alicante, Spain.
  • Kim JS; Severance Cardiovascular Hospital, Yonsei, Korea (the Republic of).
  • Freixa X; Cardiology, Hospital Clinic of Barcelona, Barcelona, Spain.
  • Lopez-Minguez JR; Cardiology, Hospital Universitario de Badajoz, Badajoz, Spain.
  • De Backer O; Cardiology, Rigshospitalet, Kobenhavn, Denmark.
  • Ruiz-Salmeron R; Cardiology, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Dominguez A; Cardiology, Hospital Universitario Virgen de la Victoria, Malaga, Spain.
  • McInerney A; Interventional Cardiology. Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.
  • Peral V; Cardiology, Hospital Universitario Son Espases, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.
  • Estevez-Loureiro R; Cardiology, University Hospital Complex Vigo, Vigo, Spain.
  • Fernandez-Nofrerias E; Interventional Cardiology, HU Germans Trias i Pujol, Badalona, Spain.
  • Freitas-Ferraz AB; Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec, Ontario, Canada.
  • Saia F; Cardiology, University Hospital of Bologna, Bologna, Italy.
  • Huczek Z; 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
  • Gheorghe L; Cardiology, Hospital Universitario Puerta del Mar, Cadiz, Spain.
  • Salinas P; Interventional Cardiology. Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.
  • Demkow M; Department of Coronary and Structural Heart Diseases, National Institute of Cardiology, Warsaw, Poland.
  • Delgado-Arana JR; Cardiology, Clinic University Hospital, Valladolid, Spain.
  • Fernandez Peregrina E; Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Kalarus Z; Silesian Centre for Heart Disease, Zabrze, Poland.
  • Elvira Laffond A; Cardiology, Hospital Universitario de Salamanca, IBSAL, CIBER CV, Salamanca, Spain.
  • Jang Y; Severance Cardiovascular Hospital, Yonsei, Korea (the Republic of).
  • Fernandez Camacho JC; Cardiology, Hospital Universitario de Badajoz, Badajoz, Spain.
  • Lee OH; Severance Cardiovascular Hospital, Yonsei, Korea (the Republic of).
  • Hernández-Garcia JM; Cardiology, Hospital Universitario Virgen de la Victoria, Malaga, Spain.
  • Mas-Llado C; Cardiology, Hospital Universitario Son Espases, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.
  • Caneiro Queija B; Cardiology, University Hospital Complex Vigo, Vigo, Spain.
  • Amat-Santos IJ; Cardiology, Clinic University Hospital, Valladolid, Spain.
  • Dabrowski M; Interventional Cardiology and Angiology Clinic, National Institute of Cardiology, Warsaw, Poland.
  • Rodés-Cabau J; Cardiology, Quebec Heart and Lung Institute, Laval University, Quebec, Ontario, Canada.
  • Nombela Franco L; Interventional Cardiology. Cardiovascular Institute, Hospital Clinico San Carlos, IdISSC, Madrid, Spain luisnombela@yahoo.com.
Heart ; 108(14): 1098-1106, 2022 06 24.
Article en En | MEDLINE | ID: mdl-34686564
ABSTRACT

OBJECTIVE:

Left atrial appendage (LAA) thrombus has heretofore been considered a contraindication to percutaneous LAA closure (LAAC). Data regarding its management are very limited. The aim of this study was to analyse the medical and invasive treatment of patients referred for LAAC in the presence of LAA thrombus.

METHODS:

This multicentre observational registry included 126 consecutive patients referred for LAAC with LAA thrombus on preprocedural imaging. Treatment strategies included intensification of antithrombotic therapy (IAT) or direct LAAC. The primary and secondary endpoints were a composite of bleeding, stroke and death at 18 months, and procedural success, respectively.

RESULTS:

IAT was the preferred strategy in 57.9% of patients, with total thrombus resolution observed in 60.3% and 75.3% after initial and subsequent IAT, respectively. Bleeding complications and stroke during IAT occurred in 9.6% and 2.9%, respectively, compared with 3.8% bleeding and no embolic events in the direct LAAC group before the procedure. Procedural success was 90.5% (96.2% vs 86.3% in direct LAAC and IAT group, respectively, p=0.072), without cases of in-hospital thromboembolic complications. The primary endpoint occurred in 29.3% and device-related thrombosis was found in 12.8%, without significant difference according to treatment strategy. Bleeding complications at 18 months occurred in 22.5% vs 10.5% in the IAT and direct LAAC group, respectively (p=0.102).

CONCLUSION:

In the presence of LAA thrombus, IAT was the initial management strategy in half of our cohort, with initial thrombus resolution in 60% of these, but with a relatively high bleeding rate (~10%). Direct LAAC was feasible, with high procedural success and absence of periprocedural embolic complications. However, a high rate of device-related thrombosis was detected during follow-up.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fibrilación Atrial / Trombosis / Apéndice Atrial / Accidente Cerebrovascular / Cardiopatías Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies Límite: Humans Idioma: En Revista: Heart Asunto de la revista: CARDIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fibrilación Atrial / Trombosis / Apéndice Atrial / Accidente Cerebrovascular / Cardiopatías Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies Límite: Humans Idioma: En Revista: Heart Asunto de la revista: CARDIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: España